Introduction
============

Sphingosine kinases 1 and 2 (SK1 and SK2) are proto-oncogenic enzymes expressed in multiple human tumors ([@B2]). They convert proapoptotic lipid second messenger sphingosine to anti-apoptotic sphingosine-1-phosphate. SKs display different subcellular localization and tissue expression patterns. SK1 is a constitutively active cytosolic enzyme, that translocates to the plasma membrane upon phosphorylation at Ser225. SK2 is localized mainly in the nucleus where it has a role in DNA synthesis and histone H3 acetylation ([@B25]).

There is compelling evidence that SK1 activation contributes to cancer progression and leads to oncogenic transformation, increased tumor growth and impairment of apoptosis (reviewed in [@B2]; [@B29]). SK1 is a tumor-associated enzyme: high levels of SK1 expression have been shown in various human tumors such as brain, breast, colon, lung, ovary, stomach, uterus, kidney, rectum, and small intestine, where they enhance tumor neovascularization and metastatic potential by promoting motility and invasion of cancer cells ([@B10]; [@B23]; [@B22]). High levels of SK1 expression or activity are associated with a poor prognosis in several human cancers, making it a key pathway in the search for targeted therapies ([@B22]). SK2 is predominantly localized to cell organelles and its role in cell proliferation/apoptosis is less well studied. However, several studies showed a critical role of SK2 for epidermal growth factor-stimulated migration of breast cancer cells, growth of tumor xenografts and lung cancer chemoresistance ([@B25]).

Multiple SK1 and SK2 inhibitors have been synthesized and assayed in different biological systems. Selective SK1 inhibitors such as SK1-I or SK-F have been demonstrated to efficiently induce apoptosis in cancer cells ([@B17]; [@B3]). A sphingosine analog FTY720 was shown to inhibit SK1 and induce cancer cell apoptosis ([@B26]; [@B20]), chemo- and radiosensitization ([@B18]; [@B5]; [@B27]). Several studies have indicated an anti-tumorigenic role of a specific SK2 inhibitor ABC294640 ([@B7]; [@B8]; [@B25]).

Oncogenic signaling pathways are complex. Intervention with a single pathway usually leads to multiple pathways being affected due to cross-regulation. Based on this rationale, identifying signaling "hubs" has become popular in molecular therapy design, hoping that by targeting one key molecule, multiple signaling pathways can be regulated. This, however, can lead to undesirable side effects. Furthermore, targeting only one pathway does not always lead to desired effects due to the presence of parallel signaling pathways leading to the same end-point, prompting the use of combined therapies. Care should be taken in the creation of combined therapeutic interventions utilizing compounds that could target independent or compensatory pathways and therefore have synergistic effects. The rationale for such combinations could be derived from studying the gene expression and pathways regulation.

In this study, we have used for the first time RNA transcriptome microarray technology to investigate the transcriptome-wide effects of SK1 and SK2 downregulation. This approach mimics the therapeutic targeting of SKs by inhibitors and allows mapping the affected/unaffected signaling cascades. Our data provide useful insight for creating more robust therapeutic combinations for cancer targeting.

Materials and Methods {#s1}
=====================

Cell Culture and Reagents
-------------------------

Human breast cancer cell lines MDA-MB-231 and BT-549 and human prostate cancer cells lines PC-3 and DU145 were purchased from ATCC (Manassas, VA, United States), and maintained in RPMI with 10% FCS, 50 U/ml penicillin, 50 μg/ml streptomycin and 2 mM glutamine (Sigma-Aldrich, St. Louis, MO, United States). Cell lines were kept in culture for up to 30 passages. Cells were seeded to reach 70--80% confluence by the end of the treatment. All chemicals unless specified were from Sigma Aldrich (Poole, United Kingdom).

RNA Interference
----------------

Cells were seeded at a density to reach 30--50% confluence by the day of transfection. Cells were transfected as described previously ([@B1], [@B4]) using siRNA directed against SK1 and SK2 as pooled four independent sequences and non-targeting siRNA as a negative control combined with HiPerFect (Qiagen, West Sussex, United Kingdom). Optimal knockdown (KD) was obtained 72 h post-transfection and verified by qRT-PCR.

RNA Extraction, cDNA Synthesis and qRT-PCR
------------------------------------------

Isolation of total RNA from cancer cells was performed using the RNeasy Mini kit (Qiagen, Valencia, CA, United States) as per manufacturer's instructions. RNA quantity and purity was measured using a NanoDrop 2000c Spectrophotometer (Thermo Fisher Scientific, Loughborough, United Kingdom). Reverse transcription was performed using Precision nanoScript^TM^ Reverse transcription kit (PrimerDesign Ltd., Southampton, United Kingdom). qRT-PCR was done as already described ([@B1], [@B5]). Ct values were exported and analyzed using qbase software (Biogazelle NV, Zwijnaarde, Belgium).

RNA Microarray
--------------

RNA was normalized to an input amount of 99.9 ng and underwent reverse transcription. sscDNA was purified using magnetic beads and fragmented using UDG. Fragmented sample was hybridized to Affymetrix Clariom S human arrays at 45°C overnight. Stained arrays are scanned to generate intensity data. All reagent kits and arrays were purchased from Thermo Fisher Scientific, Loughborough, United Kingdom.

Sphingosine Kinase Activity
---------------------------

Sphingosine kinases 1 and 2 assay was performed using radiolabeling as previously described ([@B19]; [@B1], [@B4]), in conditions favoring either SK1 or SK2 activity ([@B15]).

Statistical Analysis
--------------------

qRT-PCR data are presented as the mean values of at least three independent experiments normalized to control ± standard error of the mean (SEM) calculated using GraphPad Prism. Statistical significance between two groups was conducted by unpaired Student's *t*-test. *P*-value of \<0.05 is considered statistically significant.

DNA microarray analyses were performed in R version 3.4.3. Gene-level signal estimates were derived from CEL files generated from Affymetrix Clariom S human arrays using the multi-array analysis (RMA) algorithm ([@B13]) implemented in Bioconductor package oligo version 1.42.0 ([@B9]). Differential expression analysis was performed using the *limma* version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an empirical Bayes approach ([@B24]). A moderated *t*-statistic was computed for each transcript cluster with the resulting *p*-values adjusted for multiple testing using Benjamini and Hochberg's method to control the false discovery rate. Those transcript clusters with an adjusted *p*-value less than 0.05 were considered to be significantly differentially expressed between the two groups.

Gene ontology biological process and hallmarks of cancer gene sets were tested in gene set enrichment analysis using the clusterProfiler package, version 3.6 ([@B31]). The *t*-statistic generated in the differential expression analyses was used as the metric, with all entrez genes as the background and a cut-off *p*-value of 0.05 after multiple testing using the false discovery rate.

Results
=======

Chemotherapy and molecular therapy are currently used in treatment of locally advanced and metastatic prostate and breast cancers. Among those cancers, androgen-independent prostate tumors and triple negative breast tumors are considered the most aggressive form of the disease. As a model of those diseases, we have chosen two metastatic androgen-insensitive prostate cancer cells lines PC-3 and DU145 and two metastatic triple negative breast cancer cell lines MBA-MB-231 and BT-549. SK1 and SK2 downregulation was achieved by transfection with four pooled sequences siRNA (Qiagen) for 72 h and verified using qRT-PCR ([Figure 1](#F1){ref-type="fig"}). It is interesting to note that in PC-3 and BT-549 cells KD of SK1 caused a significant increase in SK2 expression (55 and 45%, respectively), however this effect was not present in MDA-MB-231 and DU145 cells ([Figure 1](#F1){ref-type="fig"}). These results were confirmed on the enzyme level using SK1 and SK2 activity ([Figure 1](#F1){ref-type="fig"}).

![SK1/SK2 knockdown in prostate and breast cancer cell lines. Human breast cancer cell lines MDA-MB-231 and BT-549 and human prostate cancer cells lines PC-3 and DU145 were transfected with SK1 and SK2 siRNA and gene knockdown was assessed by qRT-PCR **(A,B)**. SK1 and SK2 activity was assessed using radiolabeling assay **(C,D)**. Data mean values of at least three independent experiments normalized to control ± SEM. ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001.](fphar-10-00303-g001){#F1}

DNA CHIP analysis was performed on all samples in triplicate using Affymetrix Clariom S microarray. Genes were determined to be significantly differentially expressed using a moderated *t*-test (*p* (0.05; Benjamin Hochberg multiple testing correction applied). SK1 and SK2 regulated genes exhibited tissue specific differences. As expected, SK1 and SK2 were shown to be down-regulated by respective siRNA pools (for clarity, these effects are not shown in [Figure 2](#F2){ref-type="fig"}--[5](#F5){ref-type="fig"}).

![Altered gene expression in response to SK1 knockdown (KD) in prostate cancer cell lines. Human prostate cancer cells lines PC-3 and DU145 were transfected with SK1 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was performed using the *limma* version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an empirical Bayes approach. A moderated *t*-statistic was computed for each transcript cluster with the resulting *p*-values adjusted for multiple testing using Benjamini and Hochberg's method to control the false discovery rate. Those transcript clusters with an adjusted *p*-value less than 0.05 were considered to be significantly differentially expressed between the two groups; *bars*, SEM.](fphar-10-00303-g002){#F2}

![Altered gene expression in response to SK1 knockdown (KD) in breast cancer cell lines. Human breast cancer cell lines MDA-MB-231 and BT-549 were transfected with SK1 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was performed using the *limma* version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an empirical Bayes approach. A moderated *t*-statistic was computed for each transcript cluster with the resulting *p*-values adjusted for multiple testing using Benjamini and Hochberg's method to control the false discovery rate. Those transcript clusters with an adjusted *p*-value less than 0.05 were considered to be significantly differentially expressed between the two groups; *bars*, SEM.](fphar-10-00303-g003){#F3}

![Altered gene expression in response to SK2 knockdown (KD) in prostate cancer cell lines. Human prostate cancer cells lines PC-3 and DU145 were transfected with SK2 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was performed using the *limma* version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an empirical Bayes approach. A moderated *t*-statistic was computed for each transcript cluster with the resulting *p*-values adjusted for multiple testing using Benjamini and Hochberg's method to control the false discovery rate. Those transcript clusters with an adjusted *p*-value less than 0.05 were considered to be significantly differentially expressed between the two groups; *bars*, SEM.](fphar-10-00303-g004){#F4}

![Altered gene expression in response to SK2 knockdown (KD) in breast cancer cell lines. Human breast cancer cell lines MDA-MB-231 and BT-549 were transfected with SK2 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was performed using the *limma* version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an empirical Bayes approach. A moderated *t*-statistic was computed for each transcript cluster with the resulting *p*-values adjusted for multiple testing using Benjamini and Hochberg's method to control the false discovery rate. Those transcript clusters with an adjusted *p*-value less than 0.05 were considered to be significantly differentially expressed between the two groups; *bars*, SEM.](fphar-10-00303-g005){#F5}

In prostate cancer cells SK1 KD induced downregulation of expression of ten genes and upregulation of five genes ([Figure 2](#F2){ref-type="fig"}, only genes identically regulated in both cell lines are shown). Among the genes downregulated by SK1 were G3BP stress granule assembly factors G3BP1 and G3BP2 \[involved in nuclear factor kappa B (NFκB), RAS and Wnt signaling\], phosphoribosyl pyrophosphate synthetase 2 (PRPS2), involved in multiple biosynthesis pathways like purine synthesis, NOP2/Sun RNA methyltransferase family member 2 (NSUN2) which regulates mRNA translation and NADH:ubiquinone oxidoreductase subunit A2 (NDUFA2), a subunit of complex I of the respiratory chain. SK1 KD increased expression of IBTK (inhibitor of Bruton tyrosine kinase) and notably ETS1 (ETS proto-oncogene 1, transcription factor).

In breast cancer cells SK1 KD ([Figure 3](#F3){ref-type="fig"}) has decreased the expression of E2F5 (E2F transcription factor 5), NSUN2, nuclear factor of activated T-cells 3 (NFATC3) which regulates transcription, PRPS2, cyclin dependent kinase 2 (CDK2), known regulator in the cell cycle, G3BP stress granule assembly factors G3BP1 and G3BP2, vesicle-associated membrane-protein-associated protein B (VAPB) involved in vesicle trafficking and N-acetylglucosamine kinase (NAGK), involved in metabolism. SK1 KD has notably increased expression of RAB23 (encodes a small GTPase of the RAS oncogene superfamily).

In prostate cells, SK2 KD affected expression of 25 genes ([Figure 4](#F4){ref-type="fig"}) including downregulation of capping actin protein of muscle Z-line alpha subunit 1 (CAPZA1), involved in inhibition of autophagy and epithelial-mesenchymal transition (EMT), NSUN3 (NOP2/Sun RNA methyltransferase family member 3, mRNA translation), ADP dependent glucokinase (ADPGK), involved in EMT in cancer cells and kelch domain containing 10 (KLHDC10), which regulates oxidative stress. SK2 KD increased expression of voltage dependent anion channel 1 (VDAC1) oncogene, regulator of mammalian target of rapamycin (mTOR), inhibitor of Bruton tyrosine kinase (IBTK), antiproliferative, ataxin 10 (ATXN10) which activates the RAS-MAP kinase pathway, ETS proto-oncogene 1 (ETS1), transcription factor, ubiquitin conjugating enzyme E2 R2 (UBE2R2) involved in ubiquitination and cell differentiation, MAP kinase interacting serine/threonine kinase 2 (MKNK2), protein phosphatase 2 regulatory subunit B′alpha (PPP2R5A) and WEE1 G2 checkpoint kinase (WEE1), cell cycle regulator.

On the other hand, SK2 KD in breast cancer ([Figure 5](#F5){ref-type="fig"}) has downregulated expression of integrin subunit alpha V (ITGAV), belongs to the integrin alpha chain family which may regulate angiogenesis and cancer progression and capping actin protein of muscle Z-line alpha subunit 1 (CAPZA1), regulates growth of the actin filament and increased expression of general transcription factor IIB (GTF2B), zinc finger DHHC-type containing 20 (ZDHHC20) and ST13, Hsp70 interacting protein, involved in the assembly process of glucocorticoid receptor.

We have then performed a functional analysis of identified genes for the gene-set enrichment of known biochemical pathways upon SK1 and 2 KD. We have investigated the changes for gene ontology biological process pathways ([Figure 6](#F6){ref-type="fig"} and [Supplementary Tables S1](#SM1){ref-type="supplementary-material"}--[S4](#SM4){ref-type="supplementary-material"}) and hallmarks of cancer gene sets ([Tables 1](#T1){ref-type="table"}--[4](#T4){ref-type="table"}). SK1 and SK2 KD had different effect on pathway enrichment which was also cell line dependent, although there were several common pathways shared between both cell lines and both SKs. Gene-set enrichment analysis of gene ontology biological process enrichment pathways showed that in prostate cancer cells SK1 KD has induced downregulation of pathways linked with DNA conformation change, chromatin assembly and regulation of G1/S transition of mitotic cell cycle and notably enrichment of Wnt signaling pathway, cell motility and MAP kinase activity ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}, examples of linked pathways shown in [Figure 6](#F6){ref-type="fig"}). In breast cancer cells SK1 KD has induced a downregulation of pathways responsible for DNA replication and repair, cell cycle (G1/S), p53, enrichment in Wnt signaling and vesicle-mediated transport pathways ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}, examples of linked pathways shown in [Figure 6](#F6){ref-type="fig"}). In prostate cancer cells, SK2 KD has enriched RAS protein signal transduction, MAP kinase, protein serine/threonine kinase, cell motility, small GTPase and phosphatidylinositol 3-kinase signaling pathways ([Supplementary Table S3](#SM3){ref-type="supplementary-material"}, examples of linked pathways shown in [Figure 6](#F6){ref-type="fig"}) while in breast cancer cells it induced Wnt signaling, small GTPase mediated signal transduction, MAP kinase, endosomal transport and RAS protein signal transduction pathways and downregulated DNA repair pathway ([Supplementary Table S4](#SM4){ref-type="supplementary-material"}, examples of linked pathways shown in [Figure 6](#F6){ref-type="fig"}).

![Gene-set enrichment analysis of gene ontology biological process enrichment pathways. Human prostate cancer cells lines PC-3 and DU145 **(A,B)** and human breast cancer cell lines MDA-MB-231 and BT-549 **(C,D)** were transfected with SK1 **(A,C)** and SK2 **(B,D)** siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Gene ontology biological process and hallmarks of cancer gene sets were tested in gene set enrichment analysis using the clusterProfiler package, version 3.6. The *t*-statistic generated in the differential expression analyses was used as the metric, with all Entrez Genes as the background and a cut-off *p*-value of 0.05 after multiple testing using the false discovery rate.](fphar-10-00303-g006){#F6}

###### 

Gene-set enrichment analysis of hallmark of cancer enrichment pathways in response to SK1 KD in breast cancer cells.

  Description                                    Enrichment score   *p*-value
  ---------------------------------------------- ------------------ -----------
  HALLMARK_E2F_TARGETS                           --0.58603          0.001923
  HALLMARK_G2M_CHECKPOINT                        --0.45283          0.001905
  HALLMARK_MYC_TARGETS_V1                        --0.40462          0.001923
  HALLMARK_UV_RESPONSE_UP -0.32927               0.012121           
  HALLMARK_INFLAMMATORY\_ RESPONSE               0.285129           0.026971
  HALLMARK_KRAS_SIGNALING_UP                     0.287628           0.024896
  HALLMARK_IL2_STAT5_SIGNALING                   0.296696           0.010526
  HALLMARK_APOPTOSIS                             0.300881           0.026
  HALLMARK_GLYCOLYSIS                            0.30635            0.004149
  HALLMARK_TNFA_SIGNALING_VIA\_ NFKB             0.314365           0.004211
  HALLMARK_COMPLEMENT                            0.32964            0.004211
  HALLMARK_APICAL_JUNCTION                       0.340443           0.002075
  HALLMARK_MYOGENESIS                            0.34409            0.002105
  HALLMARK_P53_PATHWAY                           0.354588           0.002096
  HALLMARK_HYPOXIA                               0.355858           0.002105
  HALLMARK_FATTY_ACID\_ METABOLISM               0.373058           0.003984
  HALLMARK_XENOBIOTIC\_ METABOLISM               0.374965           0.002075
  HALLMARK_ADIPOGENESIS                          0.381432           0.002105
  HALLMARK_COAGULATION                           0.404393           0.001996
  HALLMARK_INTERFERON_GAMMA\_ RESPONSE           0.4096             0.00211
  HALLMARK_EPITHELIAL\_ MESENCHYMAL_TRANSITION   0.414758           0.002105
  HALLMARK_UV_RESPONSE_DN                        0.437977           0.001976

###### 

Gene-set enrichment analysis of hallmark of cancer enrichment pathways in response to SK1 KD in prostate cancer cells.

  Description                                    Enrichment score   *p*-value
  ---------------------------------------------- ------------------ -----------
  HALLMARK_UV_RESPONSE_UP                        --0.402737052      0.0027
  HALLMARK_E2F_TARGETS                           --0.382852104      0.0028
  HALLMARK_G2M_CHECKPOINT                        0.373919221        0.0028
  HALLMARK_P53_PATHWAY                           --0.311816056      0.0028
  HALLMARK_XENOBIOTIC_METABOLISM                 --0.31162798       0.0028
  HALLMARK_INTERFERON_GAMMA\_ RESPONSE           --0.308977776      0.0028
  HALLMARK_FATTY_ACID_METABOLISM                 --0.290319736      0.0134
  HALLMARK_ADIPOGENESIS                          --0.290165971      0.0057
  HALLMARK_OXIDATIVE\_ PHOSPHORYLATION           --0.273082408      0.0113
  HALLMARK_COMPLEMENT                            0.283316334        0.0246
  HALLMARK_HYPOXIA                               0.291083127        0.0185
  HALLMARK_IL2_STAT5_SIGNALING                   0.295293643        0.0154
  HALLMARK_TNFA_SIGNALING_VIA\_ NFKB             0.317881573        0.0077
  HALLMARK_MITOTIC_SPINDLE                       0.333397383        0.0046
  HALLMARK_KRAS_SIGNALING_UP                     0.367158279        0.0015
  HALLMARK_EPITHELIAL\_ MESENCHYMAL_TRANSITION   0.440097468        0.0015

###### 

Gene-set enrichment analysis of hallmark of cancer enrichment pathways in response to SK2 KD in breast cancer cells.

  Description                                    Enrichment score   *p*-value
  ---------------------------------------------- ------------------ -----------
  HALLMARK_INTERFERON_GAMMA\_ RESPONSE           --0.389698297      0.0043
  HALLMARK_ALLOGRAFT_REJECTION                   --0.339536274      0.0043
  HALLMARK_KRAS_SIGNALING_DN                     --0.28487173       0.0042
  HALLMARK_E2F_TARGETS                           --0.278165758      0.0085
  HALLMARK_G2M_CHECKPOINT                        --0.270306348      0.0129
  HALLMARK_GLYCOLYSIS                            0.317865223        0.0222
  HALLMARK_FATTY_ACID_METABOLISM                 0.326776858        0.0214
  HALLMARK_MITOTIC_SPINDLE                       0.348623881        0.0052
  HALLMARK_XENOBIOTIC_METABOLISM                 0.356201125        0.0013
  HALLMARK_HYPOXIA                               0.356508267        0.0013
  HALLMARK_APICAL_JUNCTION                       0.356988995        0.0013
  HALLMARK_EPITHELIAL\_ MESENCHYMAL_TRANSITION   0.373510215        0.0013
  HALLMARK_ADIPOGENESIS                          0.382867908        0.0013
  HALLMARK_HEME_METABOLISM                       0.390882683        0.0013
  HALLMARK_P53_PATHWAY                           0.424168593        0.0013
  HALLMARK_MYOGENESIS                            0.429404077        0.0013
  HALLMARK_UV_RESPONSE_DN                        0.445254468        0.0014

###### 

Gene-set enrichment analysis of hallmark of cancer enrichment pathways in response to SK2 KD in prostate cancer cells.

  Description                            Enrichment score   *p*-value
  -------------------------------------- ------------------ -------------
  HALLMARK_INTERFERON_GAMMA\_ RESPONSE   --0.45775          0.003021148
  HALLMARK_UV_RESPONSE_UP                --0.35239          0.002881844
  HALLMARK_FATTY_ACID\_ METABOLISM       --0.30608          0.00877193
  HALLMARK_HEME_METABOLISM               0.3308             0.004470939
  HALLMARK_E2F_TARGETS                   0.33106            0.004451039
  HALLMARK_G2M_CHECKPOINT                0.34475            0.001501502
  HALLMARK_UV_RESPONSE_DN                0.3727             0.003120125
  HALLMARK_MITOTIC_SPINDLE               0.47889            0.00148368

Gene-set enrichment analysis of hallmarks of cancer pathways has shown several important pathways regulated by SK1/SK2 KD. SK1 KD in breast cancer cell lines downregulated Myc, G2/M cell cycle and E2F pathways ([Table 1](#T1){ref-type="table"}) and upregulated KRAS, IL2/signal transducer and activator of transcription (STAT)5 and tumor necrosis factor (TNF)/NFκB pathways. Prostate cancer cell lines similarly had G2/M, E2F and additionally p53 pathways downregulated, and KRAS, IL2/STAT5, TNF/NFκB and additionally EMT pathways upregulated by SK1 KD ([Table 2](#T2){ref-type="table"}).

Sphingosine kinase 2 KD had similar effects to SK1 in breast cancer cells downregulating KRAS, G2/M and E2F pathways and upregulating EMT and p53 pathways ([Table 3](#T3){ref-type="table"}). On the contrary, in prostate cancer cells SK2 KD has upregulated G2/M and E2F pathways ([Table 4](#T4){ref-type="table"}).

Discussion
==========

In the last decade SK inhibitors have shown significant potential for cancer treatment. There are dozens of papers proving their antitumour efficacy *in vitro* and *in vivo* (reviewed in [@B2]) and two molecules are already in clinical trials: SK1 inhibitor phenoxodiol (Veyonda) for prostate cancer, non-small cell lung cancer and sarcoma; and SK2 inhibitor ABC294640 (opaganib) for advanced solid tumors and multiple myeloma. These inhibitors are often proposed to be used as "sensitisers" to chemo- and radiotherapy and can be used as free drugs or in nanoparticle settings ([@B5]; [@B27]; [@B30]). Their specificity has significantly increased with the recent discovery of SK1 structure ([@B28]) and the use of computer modeling methods ([@B3]).

Cancer progression is mediated by multiple mutations and involves activation of a wide variety of signaling pathways, many of which are cross-regulated or lead to similar downstream events (reviewed in [@B11]). For example, in cancer cell, a mutation in receptor tyrosine kinase can activate multiple signaling pathways and subsequent transcription factors leading to gene expression, while each of these pathways can be also mutated or activated independently, creating a highly complex web of signaling. The typical molecular targeting therapy approach is to block these pathways (e.g., tyrosine kinases, mTOR, MAPK, PARP, CDK, etc.) with specific inhibitors. Aside from few cases (such as BCR-Abl), where one major mutation is responsible for cancer progression, it appears that switching off one pathway is usually insufficient to completely block cancer cell growth and induce cell death. Ordinarily, targeted cancer monotherapy can end up with bypass mechanisms. Resistant clones of cancer cells evolve that can compensate for the switched off pathway by upregulating other independent pathways.

Several approaches can be used to circumvent this phenomenon. First, improved drug delivery may allow achieving higher drug concentrations in the tumor leading to higher efficacy. Second, the employment of several combined targeted or non-targeted therapies or agents that interfere with multiple cell-signaling pathways may allow making multiple hits on the cell proliferation machinery. Finally, a combination of these approaches can possibly provide a significant benefit both in terms of efficacy and reducing side effects ([@B5]; [@B27]).

When designing the successful drug combinations, one may consider which pathways are implicated in proliferation and chemoresistance in the target system, as well as the known crosstalk between these pathways. For example, if a pro-survival pathway A activates a pro-survival pathway B, but doesn't affect the pro-survival pathway C, targeting both A and B is redundant while targeting A and C may have synergistic therapeutic effect.

We have conducted this study to identify which signaling pathways are universally or tissue specifically regulated by SK1 and SK2 in prostate and breast cancers. More importantly, we questioned which common cell proliferation pathways are upregulated as compensatory mechanisms and may be responsible for resistance to anti-SK therapies. Considering that SK inhibitors may reach clinic in near future, this knowledge would allow us to hypothesize which combinational therapies may have synergistic effects.

Across all four cell lines investigated SK1 KD downregulated expression of NSUN2 (mRNA translation), PRPS2 (purine synthesis) and G3BP1,2 (NFκB, RAS, and Wnt signaling) ([Figure 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). Other notable genes decreased by SK1 KD were NDUFA2 in prostate and E2F5, NAGK, VAPB, NFATC3, CDK2 in breast cancer cell lines. SK2 KD universally downregulated expression of CAPZA1 (inhibition of autophagy and EMT) and also decreased expression of NSUN3, ADPGK and KLHDC10 in prostate and ITGAV in breast cancer cell lines ([Figure 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). From these data it appears that SK targeting carries a significant antiproliferative effect through downregulation of expression of several genes which are relevant for cell survival and division. However, individually SK1 and SK2 KD have led to upregulation of multiple genes (IBTK, GTF2B, VDAC1, GTF2B, ETS1, TTC17, IBTK, ZDHHC20, RAB23, ATXN10, ST13, ETS1, PPP2R5A, MKNK2, UBE2R2, WEE1) that regulate transcription, cell cycle, EMT, cell motility, serine/threonine kinases, small GTPases, phosphatidylinositol 3-kinase (PI3K), HSP70, Wnt, mTOR, RAS and MAPK signaling pathways ([@B14]; [@B12]; [@B16]). It is very likely that these pathways represent a cellular "compensatory" response and may be potentially contributing to SK-inhibitor resistance.

Sphingosine kinases 1 and 2 KD has up- and downregulated a significant number of genes in individual cell lines ([Supplementary Table S5](#SM5){ref-type="supplementary-material"}). This number was reduced to 15 and 25 genes for SK1 and SK2 KD, respectively, in prostate cells and 25 and 8 genes for SK1 and SK2 KD, respectively, in breast cancer cells ([Figure 2](#F2){ref-type="fig"}--[5](#F5){ref-type="fig"}, [7](#F7){ref-type="fig"}). There was some concordance of SK-regulated genes between the tissues. Five genes (DPH2 G3BP1, G3BP2, NSUN2, and TTC17) were similarly regulated by SK1 KD in prostate and breast cancer cells ([Figure 7](#F7){ref-type="fig"}). SK2 KD has regulated CAPZA1, ELMOD2, and HACD2 in a similar fashion across all four cell lines ([Figure 7](#F7){ref-type="fig"}). There was no overlap between SK1 and SK2 regulated genes.

![Venn diagram of genes regulated by SK1/SK2 knockdown (KD) in prostate and breast cell lines. Human breast cancer cell lines MDA-MB-231 and BT-549 and prostate cancer cells lines PC-3 and DU145 were transfected with SK1 or SK2 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Numbers of significantly regulated genes common to prostate or breast cell lines are shown in outer semicircles and the number of genes universally regulated by SK1 or SK2 KD in all cell lines is shown in the middle. These universal genes are listed below the circles.](fphar-10-00303-g007){#F7}

While individual genes may provide insight into altered signaling, gene-set enrichment analysis may demonstrate a bigger picture of significant pathways modulated by SK KD. Gene-set enrichment pathway analysis showed that in all cell lines SK1 KD decreased DNA conformation and replication pathways, while SK2 KD did not decrease any major pro-proliferative pathways. In contrast, there is a clear concordance in pathways upregulated in response to SK KD. SK2 KD has upregulated RAS, MAPK and small GTPase pathways, while SK1 KD has increased Wnt signaling in all four cell lines ([Supplementary Tables S1](#SM1){ref-type="supplementary-material"}--[S4](#SM4){ref-type="supplementary-material"}). In tissue specific manner, SK1 and SK2 KD individually have also increased cell motility, vesicular transport, cell motility, Rho, PI3K and serine/threonine kinase pathways. Similar to individual genes, these pathways are likely to represent the "compensatory" response of cancer cells to SKs KD and may contribute to developing resistance for anti SK therapies.

Gene-set enrichment analysis of hallmarks of cancer pathways has shown that several important pathways are upregulated in response to SK1/SK2 KD, most notably KRAS, IL2/STAT5, EMT and TNF/NFκB (SK1 KD) and EMT, G2/M and E2F (SK2 KD) ([Tables 1](#T1){ref-type="table"}--[4](#T4){ref-type="table"}). Interestingly, several well-known pathways implicated in cancer progression or apoptosis were unaffected by SK KD (such as BCL2, PARP, or many transcription factors). These pathways are also therapeutic targets and concurrent use of their inhibitors and SK inhibitors may have therapeutic advantage. For example, if one were to use SK1 inhibitor in prostate cancer, adding PI3K inhibitor may be of particular benefit as SK1 KD is upregulating PI3K pathway which may mediate resistance. Same goes for e.g., Ras pathway and SK2 in both prostate and breast cancer cells. Conversely G1/S and G2/M are both significantly inhibited by SK1 KD in breast cancer cells, therefore adding cell cycle inhibitors may be of no additional benefit.

There were no previous studies investigating transcriptome in response to SK1 KD. An opposite study was performed by [@B21], who have transfected NIH3T3 cells with SK1 and analyzed transcriptome identifying multiple genes regulated by artificially increased SK1. There, however, may be significant difference between genes regulated by baseline SK1 activity or its absence (as in our case) and artificial SK1 overexpression. From comparison of both studies it is also clear that SK1-regulated genes are tissue and cell line specific. [@B6] have described transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator fingolimod (also an SK1 inhibitor in higher doses) identifying *QGAP2, MYBL1*, and *PTPN12* that were consistently expressed at significantly higher transcript levels in response to continued administration of fingolimod in CD8^+^, CD4^+^ and CD19^+^ cells. Fingolimod has S1P receptor affinity at nanomolar range but requires micromolar levels to inhibit SK1 ([@B18]), and it is unlikely that such levels were achieved in human patients. In addition to designing combined therapies, our data may also provide an insight into the potential side effects of therapeutic SKs inhibition. Many of the identified pathways are linked with tissue development, DNA repair, apoptosis and many other pivotal physiological processes.

As any pharmacological compounds, most SK inhibitors are not uniquely targeting SKs. Some of them have higher affinity toward SK1 (e.g., SK1-I) or SK2 (e.g., ABC294640), while others inhibit both SKs (e.g., SKI-II). They may also affect activity of other kinases. We therefore focused on using a "clean method" of SKs downregulation. It is, however, possible that siRNAs may have different effect on gene expression than pharmacological inhibitors.

Conclusion
==========

Through genome-wide microarray, we have identified important molecular pathways affected and not affected by SK1 and SK2 signaling. Multiple pathways such RAS, MAPK, small GTPase, Wnt and PI3K were upregulated in response to SK KD. Additionally, several well-known pathways implicated in cancer progression or apoptosis were unaffected by SK KD (such as BCL2, PARP). Co-targeting of these pathways may present a viable therapeutic option to overcome SK inhibitor resistance in prostate and breast cancer. Further signaling studies are required to confirm the individual involvement of the identified pathways.
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